Role of OGR1 in myeloid-derived cells in prostate cancer

Oncogene

Volumn 33, Issue 2, 2014, Pages 157-164

  Yan, L ^a   Singh, L S ^a,b   Zhang, L ^a   Xu, Y ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MANIPUR UNIVERSITY   (India)

Author keywords

adoptive transfer; macrophages; MDSC; OGR1; ovarian cancer G protein coupled receptor 1

Indexed keywords

ARGINASE 1; CD11B ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 6; OVARIAN CANCER G PROTEIN COUPLED RECEPTOR 1; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CANCER INCIDENCE; CANCER SIZE; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DEVELOPMENT; EX VIVO STUDY; HOST CELL; IMMUNE DEFICIENCY; MACROPHAGE ACTIVATION; MALE; MOUSE; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; T CELL DEPLETION; T LYMPHOCYTE; TUMOR REJECTION;

MUS;

ANIMALS; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; IMMUNE TOLERANCE; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MYELOID CELLS; PROSTATIC NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84891911462     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.566     Document Type: Article

References (34)

1. Ludwig MG, Vanek M, Guerini D, Gasser JA, Jones CE, Junker U et al. Protonsensing G-protein-coupled receptors. Nature 2003; 425: 93-98
2. Im DS. Two ligands for a GPCR, proton vs lysolipid. Acta Pharmacol Sin 2005; 26: 1435-1441
3. Singh LS, Berk M, Oates R, Zhao Z, Tan H, Jiang Y et al. Ovarian cancer G proteincoupled receptor 1, a new metastasis suppressor gene in prostate cancer. J Natl Cancer Inst 2007; 99: 1313-1327
4. Li H, Wang D, Singh LS, Berk M, Tan H, Zhao Z et al. Abnormalities in osteoclastogenesis and decreased tumorigenesis in mice deficient for ovarian cancer G protein-coupled receptor 1. PLoS One 2009; 4: E5705
5. Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989; 56: 917-930
6. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997; 57: 3325-3330
7. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. Cross-Talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 2012; 22: 275-281
8. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 2007; 13(18 Pt 1): 5243-5248
9. Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 2010; 184: 3106-3116
10. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: More mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010; 59: 1593-1600
11. Luczynski W, Krawczuk-Rybak M, Stasiak-Barmuta A. [Myeloid-derived suppressor cells -The new mechanism of immunosuppression in cancer]. Postepy Hig Med Dosw (Online) 2008; 62: 18-22
12. Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res 2010; 16: 1812-1823
13. Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI. Mechanism of all-Trans retinoic acid effect on tumor-Associated myeloid-derived suppressor cells. Cancer Res 2007; 67: 11021-11028
14. Fricke I, Mirza N, Dupont J, Lockhart C, Jackson A, Lee JH et al. Vascular endothelial growth factor-Trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res 2007; 13: 4840-4848
15. Koide N, Nishio A, Sato T, Sugiyama A, Miyagawa S. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am J Gastroenterol 2004; 99: 1667-1674
16. Silliman CC, Dickey WO, Paterson AJ, Thurman GW, Clay KL, Johnson CA et al. Analysis of the priming activity of lipids generated during routine storage of platelet concentrates. Transfusion 1996; 36: 133-139
17. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor progression: Regulation by distinct molecular mechanisms. J Immunol 2008; 180: 2011-2017
18. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1-And M2-Type characteristics. J Leukoc Biol 2008; 83: 1136-1144
19. Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, Lei XF et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 2010; 101: 1913-1919
20. Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol 1995; 52: 403-413
21. Xu Y, Casey G. Identification of human OGR1, a novel G protein-coupled receptor that maps to chromosome 14. Genomics 1996; 35: 397-402
22. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010; 207: 2439-2453
23. Eruslanov E, Daurkin I, Ortiz J, Vieweg J, Kusmartsev S. Pivotal Advance: Tumormediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells. J Leukoc Biol 2010; 88: 839-848
24. Elkabets M, Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP, Apte RN et al. IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol 2010; 40: 3347-3357
25. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: Implications for translational therapeutics. Cancer 2007; 110: 1911-1928
26. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002; 62: 4499-4506
27. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56: 4096-4102
28. Rauhala HE, Porkka KP, Saramaki OR, Tammela TL, Visakorpi T. Clusterin is epigenetically regulated in prostate cancer. Int J Cancer 2008; 123: 1601-1609
29. Fasso M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N et al. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Nat Acad Sci Usa 2008; 105: 3509-3514
30. Grossmann ME, Wood M, Celis E. Expression, specificity and immunotherapy potential of prostate-Associated genes in murine cell lines. World J Urol 2001; 19: 365-370
31. Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ et al. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8 T cells: Eradication of autologous mouse prostate cancer. Cancer Res 2005; 65: 1761-1769
32. Babiarova K, Kutinova L, Zurkova K, Krystofova J, Brabcova E, Hainz P et al. Immunization with WT1-derived peptides by tattooing inhibits the growth of TRAMP-C2 prostate tumor in mice. J Immunother 2012; 35: 478-487
33. Pearson TC, Darby CR, Bushell AR, West LJ, Morris PJ, Wood KJ. The assessment of transplantation tolerance induced by anti-CD4 monoclonal antibody in the murine model. Transplantation 1993; 55: 361-367
34. Yin DP, Ma LL, Sankary HN, Shen J, Zeng H, Varghese A et al. Role of CD4 and CD8 T cells in the rejection of concordant pancreas xenografts. Transplantation 2002; 74: 1236-1241